Hy2Care, a Geleen, the Netherlands-based firm that’s advancing an injectable hydrogel, raised €4.5M in funding.
Half of the funding got here from the European Innovation Council (EIC) Fund funding awarded to Hy2Care in 2022 as a part of the EIC Accelerator. The rest was raised from Hy2Care’s current shareholders, led by Brightlands Enterprise Companions, with participation from new traders together with LIOF, the regional improvement company for Limburg.
The corporate intends to make use of the funds to finish vital preparations for its upcoming medical trial in america.
Led by CEO Leo Smit, Hy2Care is a spin-off firm of the MIRA Institute of the College Twente, the Netherlands, an institute specialised in biomedical and chemical engineering to develop an injectable hydrogel that permits pure restore of broken cartilage. Its CartRevive hydrogel implant medical trial has accomplished affected person enrolment for its EU trial in 2024 and CE marking / European market approval is anticipated by early 2026.
FinSMEs
19/05/2025
